Market Overview:
The global respiratory diseases drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, rising geriatric population, and technological advancements in respiratory drugs. The global respiratory diseases drugs market is segmented on the basis of type into over-the-counter (OTC) and prescription drugs. The OTC segment is projected to grow at a higher CAGR than the prescription drug segment during the forecast period. This growth can be attributed to factors such as ease of availability and lower cost of OTC drugs as compared with prescription drugs. On the basis of application, the global respiratory diseases drugs market is divided into hospital and retail pharmacy segments.
Product Definition:
Respiratory diseases drugs are used to treat respiratory diseases, which are diseases of the lungs and airways. They include bronchitis, pneumonia, and asthma. These drugs help to open up the airways so that patients can breathe more easily. They also help to reduce inflammation in the lungs and airways. This can help to improve breathing and reduce symptoms such as coughing and wheezing.
OTC:
OTC stands for Over-the-Counter and is used to refer to drugs that are sold without a prescription. OTC drugs can be purchased from retail stores, e-commerce websites, or drug stores. They are intended for personal use and do not require a medical prescription. Most OTC medications fall under the category of cough syrups & cold preparations or decongestants & antihistamines which help relieve symptoms of respiratory diseases such as congestion, sore throat, etc.
Rx Drugs:
Rx drugs are the ones that are available at a Reasonable Price and they should be taken as per prescription by the individuals. The respiratory diseases can be treated by using Rx drugs only if there is an underlying medical condition for which these medicines have been prescribed.
The major factor driving this market includes growing prevalence of chronic respiratory diseases along with increasing life expectancy, therefore demand for these drugs is expected to grow in future also.
Application Insights:
The global drugs market is segmented by application into hospital and retail pharmacy. The hospital segment dominated the overall application in 2017, accounting for over 70% of the revenue share. This high share is attributable to factors such as a large patient base with respiratory diseases requiring treatment, increasing prevalence of chronic respiratory diseases and growing awareness about availability of treatments for these disorders.
The retail pharmacy accounted for a significant revenue share in 2018 owing to factors such as an increase in demand for OTC medicines due to rising preference towards self-medication among patients with acute bronchitis or asthma without medical consultation, rapid growth in e-commerce platforms facilitating access to various medicines at home without having contact with healthcare professionals and easy availability of drugs through online pharmacies despite geographical restrictions on purchasing OTC medicines from traditional sources (retail pharmacies).
Regional Analysis:
North America dominated the global respiratory diseases drugs market in 2017. The presence of favorable government initiatives, high awareness levels pertaining to symptoms and treatment options, well-established healthcare infrastructure, and a large number of key players are some factors attributing to its largest share.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing disposable income levels coupled with rising health consciousness among people. Moreover, an increase in international travel has increased the prevalence of infectious diseases such as COPD globally; this is also likely to boost demand for respiratory drugs in APAC during the forecast period.
Europe accounted for a significant share due both OTC sales.
Growth Factors:
- Increasing incidence of respiratory diseases such as asthma, COPD, and pneumonia across the globe.
- Growing awareness about the available treatment options for respiratory diseases.
- Rising demand for novel and advanced therapies for respiratory diseases.
- increasing prevalence of smoking and air pollution which are the major risk factors for developing respiratory diseases .
Scope Of The Report
Report Attributes
Report Details
Report Title
Respiratory Diseases Drugs Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Retail Pharmacy
By Companies
Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck, AstraZeneca, Novartis, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Respiratory Diseases Drugs Market Report Segments:
The global Respiratory Diseases Drugs market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Pfizer
- Teva
- Novartis
- Johnson & Johnson
- EliLilly
- Otsuka
- Merck
- AstraZeneca
- Novartis
- Biogen
Highlights of The Respiratory Diseases Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Respiratory Diseases Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Respiratory diseases drugs are medications used to treat respiratory illnesses, such as bronchitis, pneumonia, and asthma. These medications can help improve your breathing and reduce the symptoms of your respiratory illness.
Some of the major companies in the respiratory diseases drugs market are Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck, AstraZeneca, Novartis, Biogen.
The respiratory diseases drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Respiratory Diseases Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Respiratory Diseases Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Respiratory Diseases Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Respiratory Diseases Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Respiratory Diseases Drugs Market Size & Forecast, 2020-2028
4.5.1 Respiratory Diseases Drugs Market Size and Y-o-Y Growth
4.5.2 Respiratory Diseases Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Respiratory Diseases Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Respiratory Diseases Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Respiratory Diseases Drugs Market: Competitive Dashboard
14.2 Global Respiratory Diseases Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Pfizer
14.3.3 Teva
14.3.4 Novartis
14.3.5 Johnson & Johnson
14.3.6 EliLilly
14.3.7 Otsuka
14.3.8 Merck
14.3.9 AstraZeneca
14.3.10 Novartis
14.3.11 Biogen
